111 related articles for article (PubMed ID: 12695855)
1. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Liu G; Oettel K; Bailey H; Ummersen LV; Tutsch K; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Rezazadeh H; McGovern J; Robinson E; DeMets D; Wilding G
Invest New Drugs; 2003 Aug; 21(3):367-72. PubMed ID: 14578686
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
Bailey HH; Levy D; Harris LS; Schink JC; Foss F; Beatty P; Wadler S
Gynecol Oncol; 2002 Jun; 85(3):464-8. PubMed ID: 12051875
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.
Meadows SM; Mulkerin D; Berlin J; Bailey H; Kolesar J; Warren D; Thomas JP
Int J Gastrointest Cancer; 2002; 32(2-3):125-8. PubMed ID: 12794248
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
Adamson PC; Widemann BC; Reaman GH; Seibel NL; Murphy RF; Gillespie AF; Balis FM
Clin Cancer Res; 2001 Oct; 7(10):3034-9. PubMed ID: 11595692
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
de Jonge MJ; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt CJ; van Oosterom A;
Eur J Cancer; 2006 Aug; 42(12):1768-74. PubMed ID: 16815702
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of perillyl alcohol in pancreatic cancer.
Matos JM; Schmidt CM; Thomas HJ; Cummings OW; Wiebke EA; Madura JA; Patrick LJ; Crowell PL
J Surg Res; 2008 Jun; 147(2):194-9. PubMed ID: 18498869
[TBL] [Abstract][Full Text] [Related]
16. Perillyl alcohol: applications in oncology.
Belanger JT
Altern Med Rev; 1998 Dec; 3(6):448-57. PubMed ID: 9855569
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol.
Reddy BS; Wang CX; Samaha H; Lubet R; Steele VE; Kelloff GJ; Rao CV
Cancer Res; 1997 Feb; 57(3):420-5. PubMed ID: 9012468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]